Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). (Q36007326)

11 August 2017

1 reference

title

Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). (English)

1 reference

11 August 2017

1 reference

1 reference

Thierry André

1

1 reference

11 August 2017

Monique Noirclerc

2

1 reference

11 August 2017

Pascal Hammel

3

1 reference

11 August 2017

Roderich Meckenstock

4

1 reference

11 August 2017

Bruno Landi

5

1 reference

11 August 2017

Stéphane Cattan

6

1 reference

11 August 2017

Frédéric Selle

7

1 reference

11 August 2017

Jean-François Codoul

8

1 reference

11 August 2017

Béatrice Guerrier-Parmentier

9

1 reference

11 August 2017

Rabia Mokhtar

10

1 reference

11 August 2017

Christophe Louvet

11

1 reference

11 August 2017

GERCOR

12

1 reference

11 August 2017

language of work or name

1 reference

1 August 2004

1 reference

Gastroenterologie Clinique et Biologique

11 August 2017

published in

1 reference

11 August 2017

volume

28

1 reference

11 August 2017

issue

8-9

1 reference

11 August 2017

page(s)

645-650

1 reference

Cancer of the pancreas. 50 years of surgery

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2804%2995042-7

7 January 2021

10.1016/S0399-8320(04)95042-7

Identifiers

DOI

1 reference

11 August 2017

1 reference